A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge

Completed · Phase 2 · Has a placebo group

Conditions studied: Allergic Rhinitis

In brief

An H3 receptor antagonist should reduce the congestion associated with allergic rhinitis. A nasal allergen challenge will be given to patients to induce rhinitis symptoms and acoustic rhinometry will be used to measure the congestion.

Key facts

Study ID

NCT00562120

Run by

Pfizer

People needed

21

Starts

2007-12-01

Expected to finish

2008-08-01

Last updated by the study team

2014-04-16

Who can join

Age: 19 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female subjects 19-55 years with allergic rhinitis requiring treatment within the previous 2 years.
• Subjects that respond to a ragweed nasal allergen challenge at screening.

You may not qualify if…

• History of asthma or FEV1 < 80% predicted.
• Significant concomitant disease or medications.
• Symptoms of allergic rhinitis within 2 weeks prior to screening.

Where it is running

• Pfizer Investigational Site — Omaha, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.